Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency

被引:140
作者
Graham, David Y. [1 ]
Tansel, Aylin [1 ,2 ]
机构
[1] Baylor Coll Med, Dept Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA
[2] 114 Doughty St,Suite 249,MSC 702, Charleston, SC 29425 USA
关键词
Efficacy Comparison; GERD; Treatment; Reflux; Drug; GASTROESOPHAGEAL-REFLUX DISEASE; ESOMEPRAZOLE; 40; MG; INTRAGASTRIC ACID CONTROL; HEALTHY MALE-SUBJECTS; LANSOPRAZOLE; 30; RABEPRAZOLE; 20; RANDOMIZED CLINICAL-TRIAL; DUODENAL-ULCER PATIENTS; PLASMA HALF-LIFE; GASTRIC-ACIDITY;
D O I
10.1016/j.cgh.2017.09.033
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Although proton pump inhibitors (PPIs) are widely used, their relative potency and ideal dosing regimens remain unclear. We analyzed data from randomized clinical trials that performed pH testing in patients receiving solid-dose PPI formulations (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) for a minimum of 5 days. We used omeprazole equivalency and the surrogate biomarker, percentage time pH > 4 over a 24-hour period (pH4time), to compare PPI effectiveness for different PPIs given once, twice, or 3 times daily. We found that increasing strength of once-daily PPIs (9-64 mg omeprazole equivalents) increased pH4time linearly from approximately 10.0 to 15.6 hours; higher doses produced no further increase in pH4time. Increasing the frequency to twice-daily PPI increased pH4time linearly, from approximately 15.8 to 21.0 hours. Three-times daily PPIs performed similarly to twice-daily PPIs. The costs of PPIs varied greatly, but the cost variation was not directly related to potency. We conclude that PPIs can be used interchangeably based on potency. Using twice-daily PPIs is more effective in increasing efficacy increasing once-daily PPI dosage. Omeprazole and lansoprazole (30 mg) and 20 mg of esomeprazole rabeprazole are functionally equivalent.
引用
收藏
页码:800 / +
页数:16
相关论文
共 107 条
[1]   Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole - comparison of 24-hour intragastric and oesophageal pH [J].
Armbrecht, U ;
Abucar, A ;
Hameeteman, W ;
Schneider, A ;
Stockbrugger, RW .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (05) :959-965
[2]   Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects [J].
Armstrong, D ;
Bair, D ;
James, C ;
Tanser, L ;
Escobedo, S ;
Nevin, K .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (07) :705-711
[3]   Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - Update 2004 [J].
Armstrong, D ;
Marshall, JK ;
Chiba, N ;
Enns, R ;
Fallone, CA ;
Fass, R ;
Hollingworth, R ;
Hunt, RH ;
Kahrilas, PJ ;
Mayrand, S ;
Moayyedi, P ;
Paterson, WG ;
Sadowski, D ;
van Zanten, SJV .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 19 (01) :15-35
[4]   Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis [J].
Ashida, K. ;
Sakurai, Y. ;
Nishimura, A. ;
Kudou, K. ;
Hiramatsu, N. ;
Umegaki, E. ;
Iwakiri, K. ;
Chiba, T. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (06) :685-695
[5]   Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis [J].
Baldi, F ;
Morselli-Labate, AM ;
Cappiello, R ;
Ghersi, S .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (06) :1357-1364
[6]   Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers [J].
Bell, N ;
Karol, MD ;
Sachs, G ;
Greski-Rose, P ;
Jennings, DE ;
Hunt, RH .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (01) :105-113
[7]   APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
BURGET, D ;
HOWDEN, CW ;
WILKINSON, J ;
HUNT, RH .
DIGESTION, 1992, 51 :59-67
[8]   The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion [J].
Blum, RA ;
Shi, H ;
Karol, MD ;
GreskiRose, PA ;
Hunt, RH .
CLINICAL THERAPEUTICS, 1997, 19 (05) :1013-1023
[9]  
Blum RA, 1998, ALIMENT PHARM THERAP, V12, P321
[10]   Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease [J].
Castell, D ;
Bagin, R ;
Goldlust, B ;
Major, J ;
Hepburn, B .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (12) :1467-1474